Joshua Zelig joined Biomark Capital in November 2013. Prior to joining the Company, Mr. Zelig was a Director at Burrill & Company and an Associate Partner at GBP Capital, a Greenwich, Connecticut-based healthcare venture firm. In that capacity he was responsible for sourcing, evaluating, and executing investment transactions and new business opportunities. Additionally, Mr. Zelig managed the firm’s intellectual property portfolios, oversaw the company’s operations, and worked closely with portfolio companies in setting and delivering strategic objectives.
Previously, Mr. Zelig was an Equity Research associate at Morgan Stanley where he covered biotech and consumer stocks. He later worked in real estate management, acquisition, and due diligence on behalf of a number of large private real estate companies as well as public REITs.
Mr. Zelig is a graduate of Yeshiva University, Sy Syms School of Business, where he received a Bachelor of Science in Finance.